# Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)

> **NCT00743964** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 91 (actual)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Cisplatin, capecitabine

## Key facts

- **NCT ID:** NCT00743964
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2010-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00743964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00743964, "Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00743964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*